Polymorphisms of the flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians

BMC Medical Genetics

Volumn 6, Issue , 2005, Pages

  Dolan, Ciara ^a   Shields, Denis C ^b   Stanton, Alice ^a   O'Brien, Eoin ^a   Lambert, Deborah M ^c   O'Brien, John K ^a   Treacy, Eileen P ^c  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c CHILDREN S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; GENOMIC DNA; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); METHYLAMINE; OXYGENASE; TRIMETHYLAMINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAUCASIAN; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEALTH SURVEY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION DISTRIBUTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; GENETICS; HYPERTENSION; INBORN ERROR OF METABOLISM; METABOLISM; MIDDLE AGED; MISSENSE MUTATION;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; HYPERTENSION; METABOLISM, INBORN ERRORS; METHYLAMINES; MIDDLE AGED; MUTATION, MISSENSE; OXYGENASES; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 29144492916     PISSN: 14712350     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-6-41     Document Type: Article

References (34)

1. KV Rudnick, DL Sackett, S Hirst, C Holmes: Hypertension in a family practice. Can Med Assoc J 1977, 117:492-7.
2. VL Rose: National Heart, Lung, and Blood Institute releases new guidelines for the treatment of hypertension. Am Fam Physician 1998, 57:362-4, 366.
3. NM Kaplan: A cardioprotective approach to the management of hypertension. J Hypertens Suppl 2000, 18:S29-31.
4. VL Burt, P Whelton, EJ Roccella, C Brown, JA Cutler, M Higgins, MJ Horan, D Labarthe: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-13.
5. D Creagh, S Neilson, A Collins, N Colwell, R Hinchion, C Drew, D O'Halloran, IJ Perry: Established cardiovascular disease and CVD risk factors in a primary care population of middle-aged Irish men and women. Ir Med J 2002, 95:298-301.
6. TW Kurtz, MA Spence: Genetics of essential hypertension. Am J Med 1993, 94:77-84.
7. NM Kaplan: Ethnic aspects of hypertension. Lancet 1994, 344:450-2.
8. P Whelton, M Klag: Hypertension in westernised populations. In: Textbook of Hypertension Edited by JDS. pp. 11-19. Oxford: Blackwell Scientific Publications; 1994: 11-19.
9. X Jeunemaitre, F Soubrier, YV Kotelevtsev, RP Lifton, CS Williams, A Charru, SC Hunt, PN Hopkins, RR Williams, JM Lalouel, et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71:169-80.
10. RP Lifton, AG Gharavi, DS Geller: Molecular mechanisms of human hypertension. Cell 2001, 104:545-56.
11. FH Wilson, S Disse-Nicodeme, KA Choate, K Ishikawa, C Nelson-Williams, I Desitter, M Gunel, DV Milford, GW Lipkin, JM Achard, MP Feely, B Dussol, Y Berland, RJ Unwin, H Mayan, DB Simon, Z Farfel, X Jeunemaitre, RP Lifton: Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-12.
12. P Hamet: Environmentally-regulated genes of hypertension. Clin Exp Hypertens 1996, 18:267-78.
13. P Hamet, Z Pausova, V Adarichev, K Adaricheva, J Tremblay: Hypertension: genes and environment. J Hypertens 1998, 16:397-418.
14. IJ Perry, PH Whincup, AG Shaper: Environmental factors in the development of essential hypertension. Br Med Bull 1994, 50:246-59.
15. OK Andersson, T Almgren, B Persson, O Samuelsson, T Hedner, L Wilhelmsen: Survival in treated hypertension: follow up study after two decades. Bmj 1998, 317:167-71.
16. MK Halushka, JB Fan, K Bentley, L Hsie, N Shen, A Weder, R Cooper, R Lipshutz, A Chakravarti: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999, 22:239-47.
17. O Smithies, N Maeda: Gene targeting approaches to complex genetic diseases atherosclerosis and essential hypertension. Proc Natl Acad Sci U S A 1995, 92:5266-72.
18. NA Holtzman, TM Marteau: Will genetics revolutionize medicine? N Engl J Med 2000, 343:141-4.
19. V Senior, TM Marteau, J Weinman: Impact of genetic testing on causal models of heart disease and arthritis: analogue studies. Phsychol Health 2000, 14:1077-88.
20. EP Treacy, BR Akerman, LM Chow, R Youil, C Bibeau, J Lin, AG Bruce, M Knight, DM Danks, JR Cashman, SM Forrest: Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 1998, 7:839-45.
21. JR Cashman, YA Bi, J Lin, R Youil, M Knight, S Forrest, E Treacy: Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem Res Toxicol 1997, 10:837-41.
22. BR Akerman, H Lemass, LM Chow, DM Lambert, C Greenberg, C Bibeau, OA Mamer, EP Treacy: Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol Genet Metab 1999, 68:24-31.
23. BR Akerman, S Forrest, L Chow, R Youil, M Knight, EP Treacy: Two novel mutations of the FMO3 gene in a proband with trimethylaminuria. Hum Mutat 1999, 13:376-9.
24. CT Dolphin, A Janmohamed, RL Smith, EA Shephard, IR Phillips: Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fishodour syndrome. Nat Genet 1997, 17:491-4.
25. JR Cashman, BR Akerman, SM Forrest, EP Treacy: Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug Metab Dispos 2000, 28:169-73.
26. J Lin, JR Cashman: Detoxication of tyramine by the flavin-containing monooxygenase: stereoselective formation of the trans oxime. Chem Res Toxicol 1997, 10:842-52.
27. AA Elfarra: Potential role of the flavin-containing monooxygenases in the metabolism of endogenous compounds. Chem Biol Interact 1995, 96:47-55.
28. DM Lambert, OA Mamer, BR Akerman, L Choiniere, D Gaudet, P Hamet, EP Treacy: In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol Genet Metab 2001, 73:224-9.
29. J Zschocke, D Kohlmueller, E Quak, T Meissner, GF Hoffmann, E Mayatepek: Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 1999, 354:834-5.
30. DJ Schaid, CM Rowland, DE Tines, RM Jacobson, GA Poland: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-34.
31. AQ Zhang, SC Mitchell, RL Smith: Exacerbation of symptoms of fish-odour syndrome during menstruation. Lancet 1996, 348:1740-1.
32. S Julius: The defense reaction: a common denominator of coronary risk and blood pressure in neurogenic hypertension? Clin Exp Hypertens 1995, 17:375-86.
33. DW Nebert: Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997, 60:265-71.
34. JLT Hartman, B Garvik, L Hartwell: Principles for the buffering of genetic variation. Science 2001, 291:1001-4.